Matches in Nanopublications for { ?s ?p "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP471766.RAuC_MJz20O17ptlK_2Yxjjk_GvK8Kdd5wP7LZQzmDOZI130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP471766.RAuC_MJz20O17ptlK_2Yxjjk_GvK8Kdd5wP7LZQzmDOZI130_provenance.
- NP697411.RAaiPuFqUHaVNOlRxZdgYk7Fbj6szfslZPK9ptAjBPcL8130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697411.RAaiPuFqUHaVNOlRxZdgYk7Fbj6szfslZPK9ptAjBPcL8130_provenance.
- NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP534130.RAKnSPKs4e5JUECtwUm_7Oq_ubnpaQC0nUScTFz3R-xHY130_provenance.
- assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731529.RAbBAkKkZ1Ky2W4k_8mnrewsoCngiTNZLThDUJVFmZwSQ130_provenance.
- NP731528.RAr8fSPL_GfpGUDpxambDRRVLuGbMHrR9rdR_UdIYGGso130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP731528.RAr8fSPL_GfpGUDpxambDRRVLuGbMHrR9rdR_UdIYGGso130_provenance.
- NP697455.RAKT7Q4zueRPsjGPj4GavsrDqPUZ1Bapj28lOBrUaC0UI130_assertion description "[Preclinical data with SGLT2 inhibitors, such as dapagliflozin and sergliflozin, show that these compounds are highly selective inhibitors for SGLT2, have beneficial effects on the glucose utilization rate, and reduce hyperglycemia while having no hypoglycemic adverse effects.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697455.RAKT7Q4zueRPsjGPj4GavsrDqPUZ1Bapj28lOBrUaC0UI130_provenance.